ENLIVEN THERAPEUTICS, INC. (ELVN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 89.15M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 40.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -124.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $89.15M | (m) | $40.81M | $-124.41M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $81.65M | (m) | $34.62M | $-115.79M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $85.86M | (m) | $34.02M | $-119.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $85.33M | (m) | $27.05M | $-112.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $88.37M | (m) | $25.04M | $-114.24M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $85.70M | (m) | $22.46M | $-110.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $80.78M | (m) | $20.17M | $-104.55M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $77.96M | (m) | $17.89M | $-100.39M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.31M | (m) | $16.12M | $-97.57M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $72.66M | (m) | $15.17M | $-93.10M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $64.57M | (m) | $12.91M | $-83.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $54.87M | (m) | $10.59M | $-70.96M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $43.09M | (m) | $8.29M | $-57.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $23.76M | (m) | $4.20M | $-7.01M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $18.94M | (m) | $2.60M | $730.00K | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $29.62M | (m) | $2.92M | $-45.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $39.83M | (m) | $3.42M | $-54.17M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $42.50M | (m) | $3.95M | $-55.82M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $38.44M | (m) | $3.85M | $-51.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $36.55M | (m) | $3.55M | $-48.66M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $35.68M | (m) | $3.19M | $-47.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $33.48M | (m) | $2.82M | $-44.63M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $32.15M | (m) | $2.23M | $-41.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $19.01M | (m) | $899.00K | $-24.12M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |